A 52-year-old man from Delhi presents with chest pain on exertion for 3 months. He has a 10-year history of type 2 diabetes and hypertension. On examination, BP is 138/88 mmHg. Lipid profile shows: Total cholesterol 285 mg/dL, LDL-C 180 mg/dL, HDL-C 35 mg/dL, Triglycerides 320 mg/dL. ECG shows nonspecific ST changes. Coronary angiography reveals 60% stenosis in the left anterior descending artery. He is started on aspirin, bisoprolol, and lisinopril. Which hyperlipidemic agent is most appropriate as first-line therapy for this patient?

Explanation

## Clinical Context This patient has established coronary artery disease (CAD) with significant dyslipidemia characterized by elevated LDL-C and triglycerides with low HDL-C. The combination of diabetes, hypertension, and angiographic evidence of CAD places him in a very high-risk category for recurrent cardiovascular events. ## Rationale for Atorvastatin **Key Point:** Statins are the gold standard first-line agents for primary and secondary prevention of cardiovascular disease in all dyslipidemic patients, particularly those with established CAD. **High-Yield:** In secondary prevention (established CAD), intensive statin therapy targeting LDL-C <70 mg/dL is recommended. Atorvastatin 40 mg is a moderate-to-high intensity regimen that can achieve this target. **Clinical Pearl:** Statins reduce cardiovascular mortality by ~20% and non-fatal MI by ~25% in CAD patients, independent of baseline LDL levels. This patient's LDL-C of 180 mg/dL requires aggressive reduction. ## Evidence Base | Feature | Statins (Atorvastatin) | Fibrates | Ezetimibe | Niacin | |---------|------------------------|----------|-----------|--------| | **LDL reduction** | 40–55% | 5–20% | 15–20% | 5–25% | | **HDL increase** | 5–10% | 10–20% | 0–5% | 15–35% | | **TG reduction** | 10–30% | 30–50% | 5–10% | 20–50% | | **CAD mortality reduction** | Proven (RCTs) | Modest | Not proven as monotherapy | Not proven as monotherapy | | **First-line in CAD** | Yes | No (adjunct) | No (adjunct) | No (adjunct) | ## Why Atorvastatin is Superior Here 1. **Proven mortality benefit in CAD** — Multiple landmark trials (4S, WOSCOPS, CARE, LIPID, HPS) demonstrate statins reduce cardiovascular death in secondary prevention. 2. **Potent LDL reduction** — Atorvastatin 40 mg typically reduces LDL by 45–50%, bringing this patient's LDL from 180 to ~90 mg/dL (target <70 in CAD). 3. **Pleiotropic effects** — Anti-inflammatory, stabilizes plaques, improves endothelial function — benefits beyond lipid lowering. 4. **Guideline consensus** — ACC/AHA, ESC, and Indian guidelines uniformly recommend statins as first-line in secondary prevention. **Mnemonic:** STATIN benefits in CAD = **S**econdary prevention proven, **T**arget LDL <70, **A**therosclerotic plaque stabilization, **T**rial-proven mortality reduction, **I**ntensive dosing, **N**o delay in initiation.